APHINITY: Pertuzumab as Adjuvant Therapy in HER2-Positive Early Breast Cancer

Rita Mehta, MD of UC Irvine Health gives an overview of the APHINITY trial and the use of pertuzumab as adjuvant therapy for patients with HER2+ early breast cancer. This was recorded at the 2017 MOAS... Author: moasc Added: 08/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts